<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:chebi fb="1" ids="18421">superoxide</z:chebi> dismutase (SOD) inhibitor, TRIEN, which enhanced the formation of gamma-induced DNA breaks in cells of healthy donors and patients with <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> and <z:e sem="disease" ids="C0005859" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Bloom syndrome</z:e> (repair-defective <z:e sem="disease" ids="C0019247" disease_type="Disease or Syndrome" abbrv="">hereditary diseases</z:e>), had virtually no effect on the formation of radioadaptive response (RAR) in these systems </plain></SENT>
<SENT sid="1" pm="."><plain>Similar results were obtained in studies on cell survival: TRIEN facilitated mortality in cells irradiated with gamma-rays but did not affect RAR formation </plain></SENT>
<SENT sid="2" pm="."><plain>TRIEN also increased the deleterious effect of <z:chebi fb="0" ids="35456">CdCl2</z:chebi>, which indicates that SOD apparently plays a certain role in cell defence against this <z:chebi fb="1" ids="25435">mutagen</z:chebi> </plain></SENT>
</text></document>